Dataset Information

Proteome Alterations during Clonal Isolation of Human Pancreatic Cancer Cell Lines

ABSTRACT: Starting from an initial cell culture (Reference), three human pancreatic cancer cell lines (MIA PaCa-2, AsPC-1 and PANC-1) were either maintained by standard cell culture (Standard) or underwent clonal isolation to obtain single-cell colonies (SCC). Emerging cell pellets of five replicates per condition were subjected to proteomic sample preparation with subsequent isobaric peptide labelling with tandem mass tags (TMTpro-16plex; leaving one channel empty). All samples of one cell line were pooled and subjected to high-pH fractionation, resulting in 12 fractions which were subsequently analyzed via explorative mass spectrometry.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Prof. Oliver Schilling

PROVIDER: MSV000088904 | MassIVE | Wed Feb 23 11:53:00 GMT 2022

REPOSITORIES: MassIVE

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Publications

Proteome alterations during clonal isolation of established human pancreatic cancer cell lines.

Bernhard P P Feilen T T Rogg M M Fröhlich K K Cosenza-Contreras M M Hause F F Schell C C Schilling O O

Cellular and molecular life sciences : CMLS 20221022 11

Clonal isolation is an integral step of numerous workflows in genome editing and cell engineering. It comprises the isolation of a single progenitor cell from a defined cell line population with subsequent expansion to obtain a monoclonal cell population. This process is associated with transient loss of cell-cell contacts and absence of a multicellular microenvironment. Previous studies have revealed transcriptomic changes upon clonal isolation with cell line specific extent. Since transcriptom ...[more]

PMID: 36271971

Similar Datasets

Project description:Zhu2015 - Combined gemcitabine and birinapant in pancreatic cancer cells - basic PD model Mathematical model to illustrate the effectiveness of combination chemotherapy involving gemcitabine and birinapant against pancreatic cancer. This model is described in the article: Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. Zhu X, Straubinger RM, Jusko WJ. J Pharmacokinet Pharmacodyn 2015 Oct; 42(5): 477-496 Abstract: Combination chemotherapy is standard treatment for pancreatic cancer. However, current drugs lack efficacy for most patients, and selection and evaluation of new combination regimens is empirical and time-consuming. The efficacy of gemcitabine, a standard-of-care agent, combined with birinapant, a pro-apoptotic antagonist of Inhibitor of Apoptosis Proteins (IAPs), was investigated in pancreatic cancer cells. PANC-1 cells were treated with vehicle, gemcitabine (6, 10, 20 nM), birinapant (50, 200, 500 nM), and combinations of the two drugs. Temporal changes in cell numbers, cell cycle distribution, and apoptosis were measured. A basic pharmacodynamic (PD) model based on cell numbers, and a mechanism-based PD model integrating all measurements, were developed. The basic PD model indicated that synergistic effects occurred in both cell proliferation and death processes. The mechanism-based model captured key features of drug action: temporary cell cycle arrest in S phase induced by gemcitabine alone, apoptosis induced by birinapant alone, and prolonged cell cycle arrest and enhanced apoptosis induced by the combination. A drug interaction term Ψ was employed in the models to signify interactions of the combination when data were limited. When more experimental information was utilized, Ψ values approaching 1 indicated that specific mechanisms of interactions were captured better. PD modeling identified the potential benefit of combining gemcitabine and birinapant, and characterized the key interaction pathways. An optimal treatment schedule of pretreatment with gemcitabine for 24-48 h was suggested based on model predictions and was verified experimentally. This approach provides a generalizable modeling platform for exploring combinations of cytostatic and cytotoxic agents in cancer cell culture studies. This model is hosted on BioModels Database and identified by: BIOMD0000000668. To cite BioModels Database, please use: Chelliah V et al. BioModels: ten-year anniversary. Nucl. Acids Res. 2015, 43(Database issue):D542-8. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

Project description:Zhu2015 - combined gemcitabine and birinapant in pancreatic cancer cells - mechanistic PD model Mechanistic mathematical model to illustrate the effectiveness of combination chemotherapy involving gemcitabine and birinapant against pancreatic cancer. This model is described in the article: Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. Zhu X, Straubinger RM, Jusko WJ. J Pharmacokinet Pharmacodyn 2015 Oct; 42(5): 477-496 Abstract: Combination chemotherapy is standard treatment for pancreatic cancer. However, current drugs lack efficacy for most patients, and selection and evaluation of new combination regimens is empirical and time-consuming. The efficacy of gemcitabine, a standard-of-care agent, combined with birinapant, a pro-apoptotic antagonist of Inhibitor of Apoptosis Proteins (IAPs), was investigated in pancreatic cancer cells. PANC-1 cells were treated with vehicle, gemcitabine (6, 10, 20 nM), birinapant (50, 200, 500 nM), and combinations of the two drugs. Temporal changes in cell numbers, cell cycle distribution, and apoptosis were measured. A basic pharmacodynamic (PD) model based on cell numbers, and a mechanism-based PD model integrating all measurements, were developed. The basic PD model indicated that synergistic effects occurred in both cell proliferation and death processes. The mechanism-based model captured key features of drug action: temporary cell cycle arrest in S phase induced by gemcitabine alone, apoptosis induced by birinapant alone, and prolonged cell cycle arrest and enhanced apoptosis induced by the combination. A drug interaction term Ψ was employed in the models to signify interactions of the combination when data were limited. When more experimental information was utilized, Ψ values approaching 1 indicated that specific mechanisms of interactions were captured better. PD modeling identified the potential benefit of combining gemcitabine and birinapant, and characterized the key interaction pathways. An optimal treatment schedule of pretreatment with gemcitabine for 24-48 h was suggested based on model predictions and was verified experimentally. This approach provides a generalizable modeling platform for exploring combinations of cytostatic and cytotoxic agents in cancer cell culture studies. This model is hosted on BioModels Database and identified by: BIOMD0000000669. To cite BioModels Database, please use: Chelliah V et al. BioModels: ten-year anniversary. Nucl. Acids Res. 2015, 43(Database issue):D542-8. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.